当前位置：
X-MOL 学术
›
CA: Cancer J. Clin.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Critical care management of chimeric antigen receptor T-cell therapy recipients
CA: A Cancer Journal for Clinicians ( IF 503.1 ) Pub Date : 2021-10-06 , DOI: 10.3322/caac.21702 Alexander Shimabukuro-Vornhagen 1, 2 , Boris Böll 1, 2 , Peter Schellongowski 2, 3 , Sandrine Valade 4 , Victoria Metaxa 5 , Elie Azoulay 4 , Michael von Bergwelt-Baildon 2, 6, 7, 8, 9, 10
CA: A Cancer Journal for Clinicians ( IF 503.1 ) Pub Date : 2021-10-06 , DOI: 10.3322/caac.21702 Alexander Shimabukuro-Vornhagen 1, 2 , Boris Böll 1, 2 , Peter Schellongowski 2, 3 , Sandrine Valade 4 , Victoria Metaxa 5 , Elie Azoulay 4 , Michael von Bergwelt-Baildon 2, 6, 7, 8, 9, 10
Affiliation
|
Chimeric antigen receptor (CAR) T-cell therapy is a promising immunotherapeutic treatment concept that is changing the treatment approach to hematologic malignancies. The development of CAR T-cell therapy represents a prime example for the successful bench-to-bedside translation of advances in immunology and cellular therapy into clinical practice. The currently available CAR T-cell products have shown high response rates and long-term remissions in patients with relapsed/refractory acute lymphoblastic leukemia and relapsed/refractory lymphoma. However, CAR T-cell therapy can induce severe life-threatening toxicities such as cytokine release syndrome, neurotoxicity, or infection, which require rapid and aggressive medical treatment in the intensive care unit setting. In this review, the authors provide an overview of the state-of-the-art in the clinical management of severe life-threatening events in CAR T-cell recipients. Furthermore, key challenges that have to be overcome to maximize the safety of CAR T cells are discussed.
中文翻译：
嵌合抗原受体 T 细胞治疗接受者的重症监护管理
嵌合抗原受体 (CAR) T 细胞疗法是一种很有前途的免疫治疗概念，正在改变血液系统恶性肿瘤的治疗方法。CAR T 细胞疗法的发展代表了将免疫学和细胞疗法的进展成功转化为临床实践的典型例子。目前可用的 CAR T 细胞产品在复发/难治性急性淋巴细胞白血病和复发/难治性淋巴瘤患者中显示出高反应率和长期缓解。然而，CAR T 细胞疗法可能会引发严重的危及生命的毒性，例如细胞因子释放综合征、神经毒性或感染，这需要在重症监护室环境中进行快速和积极的医疗治疗。在本次审查中，作者概述了 CAR T 细胞受体严重危及生命事件的临床管理最新技术。此外，还讨论了为最大限度地提高 CAR T 细胞的安全性而必须克服的关键挑战。
更新日期：2021-10-06
中文翻译：
嵌合抗原受体 T 细胞治疗接受者的重症监护管理
嵌合抗原受体 (CAR) T 细胞疗法是一种很有前途的免疫治疗概念，正在改变血液系统恶性肿瘤的治疗方法。CAR T 细胞疗法的发展代表了将免疫学和细胞疗法的进展成功转化为临床实践的典型例子。目前可用的 CAR T 细胞产品在复发/难治性急性淋巴细胞白血病和复发/难治性淋巴瘤患者中显示出高反应率和长期缓解。然而，CAR T 细胞疗法可能会引发严重的危及生命的毒性，例如细胞因子释放综合征、神经毒性或感染，这需要在重症监护室环境中进行快速和积极的医疗治疗。在本次审查中，作者概述了 CAR T 细胞受体严重危及生命事件的临床管理最新技术。此外，还讨论了为最大限度地提高 CAR T 细胞的安全性而必须克服的关键挑战。
京公网安备 11010802027423号